Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370483 · ClinicalTrials.gov registry record · Early Phase 1
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
A Early Phase 1 study of Smoldering Plasma Cell Myeloma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT04370483: Active Early Phase 1 study of Smoldering Plasma Cell Myeloma, sponsored by City of Hope Medical Center.
NCT04370483 is a Early Phase 1 study of Smoldering Plasma Cell Myeloma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 1 participants, below the 139-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04370483, a Early Phase 1 study of Smoldering Plasma Cell Myeloma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression. Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The information learned from this study will help researchers to learn more about the anti-myeloma activity of leflunomide, and whether it may delay the onset of symptomatic multiple myeloma in patients with high-risk smoldering multiple myeloma.
Primary Outcome
Will be defined by International Myeloma Working Group (IMWG) criteria. Progression to overt multiple myeloma is always considered progressive disease.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Leflunomide
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2026-11-10 |
| Phase | Early Phase 1 |
What the registry record for NCT04370483 still lists
NCT04370483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 139-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Smoldering Plasma Cell Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04370483 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04370483 about?
NCT04370483 is a clinical study titled "Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma". This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression. Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some ...
What is the current status of trial NCT04370483?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2020-10-08. Estimated completion is 2026-11-10.
What conditions does trial NCT04370483 study?
This clinical trial studies the following conditions: Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT04370483?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Leflunomide (DRUG).
Who is sponsoring clinical trial NCT04370483?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04370483 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04370483's enrollment target sits among peer trials
1 10th of 9 the lowest of 9 other Smoldering Plasma Cell Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Plasma Cell Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Early Phase 1
-
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
RECRUITING
-
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
RECRUITING · Phase 3
-
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
RECRUITING · NA
-
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI